No attachments available.
A--Drug Manufacturing and Formulation Program (DMFP)
Contact and place of performance
PLUGGE, RIEKA N
Menlo Park, CA
USA
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
The National Institutes of Health, National Institute on Drug Abuse (NIDA), awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP) on May 4, 2026. This program carries a maximum ordering value of $49,999,999.00 and an ordering period extending through May 3, 2036. Concurrently with the base awards, the agency issued initial firm-fixed-price task orders to each awardee totaling $5,000.00, with a performance period effective from May 4, 2026, through July 3, 2026.
This requirement is classified under NAICS code 325412 for Pharmaceutical Preparation Manufacturing and PSC AN11 for Health R&D Services; Health Care Services; Basic Research. The primary place of performance for this program is Menlo Park, California. This award notice, identified by solicitation number 75N95024R00077, carries no set-aside designation. Rieka N. Plugge serves as the point of contact for this action.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.